生长抑素类药物联合前列地尔对高脂血症急性胰腺炎疗效的Meta分析  

Meta-analysis:Clinical Efficacy of Somatostatin Combination with Alprostadil in the Treatment of Hyperlipidemia Acute Pancreatitis

作　　者：张波 颜廷爽 李锋 ZHANG Bo ,YAN Ting-shuang,LI Feng(Department of Intensive Care Unit,People＇s Hospital of Zhangqiu District,Jinan 250200,China)

机构地区：[1]济南市章丘区人民医院重症医学科,济南250200

出　　处：《微循环学杂志》2018年第3期58-63,70,共7页Chinese Journal of Microcirculation

摘　　要：目的:通过Meta分析评价生长抑素类药物联合前列地尔治疗高脂血症急性胰腺炎(HLAP)的疗效。方法:计算机检索维普科技期刊数据库(VIP)(1989-2018)、万方数据库(1999-2018)、中国知网数据库(CNKI)(1994-2018)、中国学术期刊网络出版总库(CAJD)(1995-2018)、PubMed,Web of Science及Cochrane Library数据库关于生长抑素类药物联合前列地尔治疗HLAP疗效的临床随机对照试验(RCT),对符合要求的RCT进行Meta分析。结果:最终纳入14篇RCT,共有932例患者符合纳入标准。Meta分析结果显示,生长抑素类药物联合前列地尔治疗HLAP的临床有效率[Z=5.51,OR=3.11,95%CI(2.08,4.65),P<0.01]显著高于生长抑素类药物治疗;临床症状缓解时间[Z=6.69,MD=-3.46,95%CI(-4.48,-2.45),P<0.01],血淀粉酶转阴时间[总效应Z=5.31,MD=-3.45,95%CI(-4.73,-2.18),P<0.01],住院时间[Z=2.68,MD=-4.99,95%CI(-8.65,-1.34),P=0.007]较生长抑素类药物治疗显著缩短,但甘油三酯(TG)降低水平[Z=1.36,MD=-3.25,95%CI(-7.94,-3.27),P=0.17]与生长抑素类药物治疗无统计学差异。结论:在常规治疗的基础上,生长抑素类药物联合前列地尔治疗HLAP的疗效确切,且明显优于生长抑素类药物治疗。Objective：To carry out a meta-analysis on the published data in order to evaluate the clinical efficacy of somatostatin combination with alprostadil in the treatment of hyperlipidemia acute pancreatitis（HLAP）.Method：A comprehensive search was performed in VIP（1989-2018）,WANFANG（1999-2018）,CNKI（1994-2018）,CAJD（1995-2018）,PubMed,Web of Science and Cochrane Library databases to collect the randomized controlled trials（RCTs）which to somatostatin combination with alprostadil in the treatment of HLAP,and to analyze the RCTs in meta-analysis method.Results：932 patients were analyzed in the 14 RCTs which met the inclusion criteria.The metaanalysis results suggested that,compared with the somatostatin treatment group,there were higher clinical effect rates（test for overall effect：Z=5.51,OR =3.11,95%CI（2.08,4.65）,P〈0.01）,shorter time of clinical symptom relief（test for overall effect：Z=6.69,MD=-3.46,95%CI（-4.48,-2.45）,P〈0.01）,shorter time of serum amylase turning to the negative（test for overall effect：Z=5.31,MD=-3.45,95%CI（-4.73,-2.18）,P〈0.01）and shorter hospital stays（test for overall effect：Z=2.68,MD=-4.99,95%CI（-8.65,-1.34）,P=0.007）in somatostatin combination with alprostadil treatment group,but level of TG（test for overall effect：Z=1.36,MD=-3.25,95%CI（-7.94,-3.27）,P=0.17）was no statistical difference.Conclusion：On the basis of conventional treatment,the clinical efficacy of somatostatin combination with alprostadil in the treatment of HLAP is positive,and better than somatostatin treatment.

关 键 词：高脂血症胰腺炎 生长抑素 前列地尔 疗效 META分析 

分 类 号：R576[医药卫生—消化系统]